A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management

International Journal of Clinical Practice

Volumn 63, Issue 10, 2009, Pages 1479-1488

  Louis, R ^a   Joos, G ^b   Michils, A ^c   Vandenhoven, G ^d  

^a CHU SART TILMAN   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; GLUCOCORTICOID; ANTIASTHMATIC AGENT; BUDESONIDE; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ADULT; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; BELGIUM; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SORE THROAT; ADOLESCENT; AGED; CHILD; COMPARATIVE STUDY; ECONOMICS; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; NEBULIZER; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW; PHYSIOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; CHILD; DRUG COSTS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW RATE; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349239109     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02185.x     Document Type: Article

References (19)

1. Global Initiative for Asthma. National Heart and Lung Institute, National Institutes of Health USA, and the world health Organization. http://www.ginasthma.org (accessed November 2006).
2. Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001 163 : 32 6.
3. Engel T, Dirksen A, Heinig JH, Nielsen NH, Weeke B, Johansson SA. Single-dose inhaled budesonide in subjects with chronic asthma. Allergy 1991 46 : 547 553.
4. Pauwels RA, Lofdahl CG, Postma DS et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997 337 : 1405 1411.
5. Zetterstrom O, Buhl R, Mellem H et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001 18 : 262 268.
6. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007 29 : 587 595.
7. O'Byrne PM, Bisgaard H, Godard PP et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005 171 : 129 136.
8. Scicchitano R, Aalbers R, Ukena D et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004 20 : 1403 1418.
9. Bousquet J, Boulet LP, Peters MJ et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007 101 : 2437 2446.
10. Kuna P, Peters MJ, Manjra AI et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007 61 : 725 736. (Pubitemid 46587876)
11. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006 368 : 744 753.
12. Rabe KF, Pizzichini E, Stallberg B et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006 129 : 246 256.
13. Vogelmeier C, D'Urzo A, Pauwels R et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005 26 : 819 828.
14. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005 99 : 553 558.
15. Campbell JL, Kiebert GM, Partridge MR. Development of the satisfaction with inhaled asthma treatment questionnaire. Eur Respir J 2003 22 : 127 134.
16. Lundborg M, Wille S, Bjermer L et al. Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study. Curr Med Res Opin 2006 22 : 809 821.
17. Sears MR, Boulet LP, Laviolette M et al. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma. Eur Respir J 2008 31 : 982 989.
18. Tattersfield AE, Lofdahl CG, Postma DS et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001 357 : 257 261.
19. Price D, Wiren A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007 62 : 1189 1198. (Pubitemid 47374022)